脑心通治疗血管性认知障碍的临床研究  

A clinical observation of the treatment with Naoxintong capsule in the vascular cognitive impairment

作　　者：刘汉兴[1] 章军建[1] 王庆 郭宏伟[3] 

机构地区：[1]武汉大学中南医院神经内科,430071 [2]武汉市第九医院神经内科 [3]武汉市武昌铁路医院内科

出　　处：《卒中与神经疾病》2011年第2期103-105,共3页Stroke and Nervous Diseases

摘　　要：目的评价脑心通胶囊治疗血管性认知障碍的临床疗效和安全性。方法本研究从三个分中心招募血管性认知功能障碍(VCI)患者240例,并随机分为治疗组121例,其中无痴呆血管认知功能障碍(VCIND)患者45例,血管性痴呆(VaD)患者76例;对照组120例,其中VCIND患者44例,VaD患者76例。治疗组给予脑心通胶囊每日口服3次,每次4粒;对照组给予复方丹参片每日口服3次,每次4粒,连续服用3月。比较不同阶段的VCI患者治疗前后简易智能精神状态量表(MMSE)、日常生活能力量表(ADL)的变化。结果治疗组VCIND患者治疗后MMSE和ADL评分均有明显改善,差异有统计学意义(P<0.01)。治疗组VaD患者治疗后MMSE略有改善,差异无统计学意义(P>0.05),而ADL评分有改善,差异有统计学意义(P<0.01)。结论脑心通胶囊能够改善无痴呆血管性认知障碍(VCIND)患者的认知功能。Objective To assess the efficacy and safety of Naoxintong capsule in vascular cognitive impairment （VCI）. Methods 241 patients with VCI were randomly divided into the treatment group [In = 121, VCI without dementia （VCIND） ： 45, vascular dementia （VaD） ： 76] and the control group （n = 120, VCIND： 44,VaD.76）. The cases of treatment group were treated with Naoxintong capsule （4 tables Tid） and the control group were treated with Dan-shen （4 tables Tid）. The duration of therapy was three months. MMSE and ADL were used to evaluate outcome. Results The scores of both MMSE and ADL were higher in the VCIND treatment group. In the VaD treatment group, the scores of ADL but not MMSE indicated clinical improvement significantly. Conclusions Naoxintong may imorove cognitive function in patient with VCIND.

关 键 词：脑心通 血管性认知障碍 临床研究 

分 类 号：R749.13[医药卫生—神经病学与精神病学]